RT Journal Article
SR Electronic
T1 Using a novel echo-marker to identify high mortality risk patients with moderate aortic stenosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.21.21265320
DO 10.1101/2021.10.21.21265320
A1 Chao, Chieh-Ju
A1 Agasthi, Pradyumma
A1 Barry, Timothy
A1 Girardo, Marlene
A1 Seri, Amith R.
A1 Shanbhag, Anusha
A1 Wang, Yuxiang
A1 Lester, Steven J.
A1 Alsidawi, Said
A1 Freeman, William K
A1 Naqvi, Tasneem Z.
A1 Eleid, Mackram
A1 Fortuin, David
A1 Sweeney, John P.
A1 Pollak, Peter
A1 Sabbagh, Abdallah El
A1 Sell-Dottin, Kristen
A1 Majdalany, David
A1 Larsen, Carolyn
A1 Holmes, David R
A1 Oh, Jae K.
A1 Appleton, Christopher P.
A1 Arsanjani, Reza
YR 2021
UL http://medrxiv.org/content/early/2021/10/22/2021.10.21.21265320.abstract
AB Background Recent studies have shown that patients with moderate aortic stenosis and reduced left ventricular ejection fraction may benefit from earlier intervention instead of periodic surveillance. Identifying patients at higher risk is therefore warranted concerning the possibility of expanding aortic valve replacement indication.Objective We aim to investigate the usefulness of a novel echo-marker, augmented mean arterial pressure (AugMAP), in identifying high-risk patients with moderate aortic stenosis.Methods Adult patients with moderate aortic stenosis (aortic valve area 1.0-1.5 cm2) at Mayo Clinic sites in 1/2010-12/2020 were identified. Baseline demographics, echocardiography, and all-cause mortality data were retrieved. Patients were grouped into higher and lower AugMAP groups using a cutoff of 80 mmHg for analysis. Kaplan-Meier and Cox regression analyses were used to assess the performance of AugMAP.Results A total of 4,563 patients with moderate aortic stenosis were included. The mean age was 73.7±12.5 years and 60.5 % were male. The median follow-up was 2.5 years, and 36.0% of patients died. The mean LVEF was 60.1 ± 11.4%, and the mean AugMAP was 99.1 ± 13.1 mmHg. Patients in the lower AugMAP group, with either preserved or reduced LVEF, had significantly worse survival performance (all p< 0.0001). Multivariate Cox regression showed that AugMAP was independently associated with all-cause mortality after adjusting for age, sex, and LVEF (HR: 0.99 per unit increase, 95%CI: 0.978-0.996, p=0.01).Conclusion AugMAP is a simple and effective echo-maker beyond LVEF to identify high-risk moderate aortic stenosis patients who may benefit more from earlier intervention.Condensed abstract Patients with moderate aortic stenosis and reduced left ventricular ejection fraction may benefit from earlier intervention. We aim to validate the usefulness of a novel echo-marker, augmented mean arterial pressure (AugMAP), in identifying high-risk patients with moderate aortic stenosis. AugMAP can identify patients at higher mortality risk within the first two years after the diagnosis of moderate aortic stenosis, regardless of LVEF. AugMAP was also independently associated with all-cause mortality after adjusting for age, sex, and LVEF. AugMAP is a simple and effective novel echo-maker beyond LVEF to identify high-risk moderate aortic stenosis patients who may benefit from earlier intervention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of Mayo Clinic gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNAASaortic stenosisAVGaortic valve gradientAugSBPaugmented systolic blood pressureAugMAPaugmented mean arterial pressureCOcardiac outputDBPdiastolic blood pressureMAPmean arterial pressureSBPsystolic blood pressureSVIstroke volume indexSAVRsurgical aortic valve replacementTAVRtranscatheter aortic valve replacementZvavalvulo-arterial impedance